Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Intranasal Fentanyl Spray (INFS)
Takeda
Break Through Pain
1 trial -
Intravenous Ibuprofen
CUMBERLAND PHARMACEUTICALS INC
Postoperative Pain
1 trial -
Intravenous ibuprofen
CUMBERLAND PHARMACEUTICALS INC
Tonsillectomy
1 trial -
LAMIVUDINE AND DOLUTEGRAVIR , DARUNAVIR , DORAVIRINE , DARUNAVIR AND COBICISTAT , EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT, TENOFOVIR ALAFENAMIDE , RITONAVIR , ISLATRAVIR/LENACAPAVIR, LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR AND COBICISTAT, EMTRICITABINE, RALTEGRAVIR , EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, EMTRICITABINE, TENOFOVIR DISOPROXIL AND RILPIVIRINE, DOLUTEGRAVIR , LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE,
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN
Ningbo Cancer Hospital
Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size β₯ 50mm.
1 trial -
LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT
Stemline Therapeutics B.V.
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence
1 trial -
LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test
Sanofi-aventis Healthcare Pty Ltd
Pruritus
1 trial -
MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE
Merck Sharp and Dohme
Breast cancer, Ovarian cancer, Endometrial cancer
1 trial -
METHYLPREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion., Obinutuzumab placebo, Myfenax 500 mg film-coated tablets, DIPHENHYDRAMINE , PARACETAMOL
Hoffmann-La Roche
Lupus Nephritis (LN)
1 trial -
MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL
Lacuna Pharma Pty Ltd
General anaesthesia
1 trial -
MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB
Merck Sharp and Dohme
Colorectal Cancer
1 trial -
MORPHINE SULFATE, KETAMINE, FENTANYL CITRATE, SODIUM CHLORIDE, SODIUM CHLORIDE
Pari Pharma GmbH
urgency, limb injuries
1 trial -
MYCOPHENOLIC ACID, -, MYCOPHENOLATE MOFETIL, VAY736, TENOFOVIR ALAFENAMIDE , ENTECAVIR , TENOFOVIR DISOPROXIL
Novartis Pharmaceuticals
Lupus nephritis
1 trial -
MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringeβ―, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL
Novartis Pharmaceuticals
Lupus nephritis
1 trial -
Melflufen
Oncopeptides AB (publ)
Multiple Myeloma
1 trial -
Micofenolato de mofetil Generis 250 mg CΓ‘psulas, Inflectra 100 mg powder for concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Oxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie
AstraZeneca AB
Advanced Biliary Tract Cancers
1 trial -
Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p
AstraZeneca AB
Endometrial Cancer
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., LENVATINIB, YERVOY 5 mg/ml concentrate for solution for infusion, Sorafenib 200mg Film-Coated Tablets
Bristol-Myers Squibb Australia Pty Ltd
Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma
1 trial -
ORAVESCENT Fentanyl Citrate
Teva Pharma GmbH
Chronic Neuropathic Pain
1 trial -
ORAVESCENT Fentanyl Citrate
Teva Pharma GmbH
Chronic Low Back Pain
1 trial -
OraVescent Fentanyl
Teva Pharma GmbH
Low Back Pain
1 trial -
OraVescent Fentanyl
Teva Pharma GmbH
Pain
1 trial -
OraVescent fentanyl (OVF)
Teva Pharma GmbH
Pain
1 trial -
OraVescent fentanyl citrate
Teva Pharma GmbH
Pain
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources